Withdrawal of rofecoxib - a wake up call for drug safety.
Mishra
P
P
Dept. of Pharmacology, Manipal College of Medical Sciences Pokhara, Nepal.
Palaian
S
S
D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009390:Nepal; D012449:Safety; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib